Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy
1Department of Vitreoretinal Surgery, Singapore National Eye Centre, Singapore, Singapore.
Eye (London, England)
|August 30, 2008
Summary
Photodynamic therapy (PDT) with verteporfin demonstrated efficacy in treating polypoidal choroidal vasculopathy (PCV), with over half of treated eyes maintaining or improving vision. Further randomized trials are needed to confirm these findings for PCV treatment.
Area of Science:
- Ophthalmology
- Medical research
- Retinal diseases
Background:
- Polypoidal choroidal vasculopathy (PCV) is a significant cause of vision loss.
- Photodynamic therapy (PDT) with verteporfin is a potential treatment modality for PCV.
Observation:
- A retrospective case series analyzed 41 eyes of 40 patients with PCV treated with PDT and verteporfin.
- Patients were monitored for at least 12 months post-treatment, with visual acuity assessed regularly.
Findings:
- Overall, 58.5% of eyes with PCV achieved stable or improved vision (loss of ≤3 lines) after a mean follow-up of 23.7 months.
- Treatment success varied by lesion location: 70% of juxtafoveal lesions and 54.8% of subfoveal lesions showed stable or improved vision.
- The majority of treated eyes (80.5%) developed quiescent scars, though some exhibited persistent leakage or choroidal neovascularization.
Implications:
- PDT with verteporfin shows promise for managing vision in patients with PCV.
- Larger, randomized controlled trials are necessary to definitively establish the efficacy of PDT for PCV.
